Patents Assigned to Caelus Pharmaceuticals B.V.
-
Patent number: 10857189Abstract: A method for preventing and/or treating vitamin B12 deficiency is taught. The method comprises administering a composition comprising pseudovitamin B12-producing bacteria, optionally in conjunction with mucin-degrading and/or propionate-producing bacteria, to a subject in need thereof. The method is particularly suitable for administration to subjects suffering from vitamin B12 deficiency due to metformin treatment for type-2 diabetes, and to subjects having undergone bariatric surgery.Type: GrantFiled: February 27, 2017Date of Patent: December 8, 2020Assignee: Caelus Pharmaceuticals B.V.Inventor: Willem Meindert De Vos
-
Patent number: 10806758Abstract: A method for culturing and preserving the probiotic gut microorganism Eubacterium hallii is disclosed. The method provides an E. hallii preparation that is suitable for administration or ingestion to humans and that provides high E. hallii biomass yields. Preferably, the medium used for culturing E. hallii to high biomass yields comprises food grade components only, is free of any animal sources, and/or is kosher. Further, including a method of treating disease using the E. hallii preparation.Type: GrantFiled: January 2, 2017Date of Patent: October 20, 2020Assignee: Caelus Pharmaceuticals B.V.Inventors: Willem Meindert De Vos, Jozef Franciscus Maria Louis Seegers
-
Patent number: 9623055Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.Type: GrantFiled: July 11, 2016Date of Patent: April 18, 2017Assignees: Academisch Medisch Centrum, Caelus Pharmaceuticals B.V.Inventors: Max Nieuwdorp, Willem Meindert De Vos
-
Publication number: 20160317589Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.Type: ApplicationFiled: July 11, 2016Publication date: November 3, 2016Applicants: Academisch Medisch Centrum, Caelus Pharmaceuticals B.V.Inventors: Max Nieuwdorp, Willem Meindert De Vos
-
Patent number: 9433650Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.Type: GrantFiled: August 30, 2012Date of Patent: September 6, 2016Assignees: Academisch Medisch Centrum, Caelus Pharmaceuticals B.V.Inventors: Max Nieuwdorp, Willem Meindert De Vos